ZYME
Zymeworks Inc.
NASDAQ · Healthcare · Biotechnology · CA
$29.19
−2.37%Aug 15, 2026, 11:59 UTC
Halper Sadeh LLC announced an investigation into Theravance Biopharma's pending acquisition by Zymeworks Inc. to determine whether shareholders are receiving a fair price and whether the board complied with securities laws and fiduciary duties.
Source:Aug 10, 2026, 12:30 UTC
Theravance Biopharma entered into a definitive agreement to be acquired by Zymeworks, expected to close in the second half of 2026.
Aug 7, 2026, 00:12 UTC
Zymeworks Inc. reported a Q2 2026 loss of $0.62 per share, missing the Zacks Consensus Estimate of a $0.56 loss, and compared to earnings of $0.03 per share a year ago.
Source:Jun 29, 2026, 00:00 UTC
Theravance Biopharma Inc. agreed to be acquired by Zymeworks Inc. via a merger in which each Theravance ordinary share will be converted into $17.00 in cash plus one contingent value right.
Jun 18, 2026, 12:00 UTC
Gandeeva Therapeutics and Zymeworks partnered to use cryo-EM for antibody drug discovery.
Source:Jun 14, 2026, 22:05 UTC
Zymeworks Inc. presented new Phase 1 clinical data for its drug candidate ZW191 at the ESMO Gynaecological Cancers Congress 2026.
Source: